Cancerul mamar metastazant &icirc;n Republica Moldova

Machidon Vitalie; Sofroni Larisa; Jovmir Vasile; Tcaciuc Diana

Articolul precedent

Articolul urmator

279

Ultima descărcare din IBN:
2024-01-04 14:56

SM ISO690:2012

MACHIDON, Vitalie, SOFRONI, Larisa, JOVMIR, Vasile, TCACIUC, Diana. Cancerul mamar metastazant în Republica Moldova. In: Conferintele Institutului Regional de Oncologie Iasi , 23-26 noiembrie 2017, Iași. Iași, România: Institutul Regional de Oncologie Iasi, 2017, Vol. 6, pp. 191-192.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Conferintele Institutului Regional de Oncologie Iasi
Vol. 6, 2017

Conferința "Conferintele Institutului Regional de Oncologie Iasi"
Iași, Romania, 23-26 noiembrie 2017

Cancerul mamar metastazant în Republica Moldova

Metastazant breast cancer in Republic of Moldova

Pag. 191-192

Machidon Vitalie, Sofroni Larisa, Jovmir Vasile, Tcaciuc Diana

IMSP Institutul Oncologic

Disponibil în IBN: 5 octombrie 2022

Descarcă PDF

Rezumat

Introducere: Cancerul mamar (CM) este responsabil de peste 100.000 decese/an în Europa. În Republica Moldova atestăm 673 decese anual (2016). Material şi metode: Studiu retrospectiv, 309 paciente cu CM metastatic din 1985, 2005 şi 2015. Rezultate: Piscul dezvoltării CM metastatic pe parcursul a 30 ani: în 1985 şi în 2005 se menţine la vârsta de 41-50 ani, respectiv: 38.7% şi 42.2%, versus 48.2% în 2015 cu vârsta de 51-60 ani. Atestăm o progresare mai lentă a metastazelor până la 3 ani în 1985 – 61.4%, în 2005 76.8% şi 71.4% în 2015. Progresarea CM revine la un ritm mai stabil după 5 ani: 11.9%, 13.6% şi 12.5%. Conform stadiului, procesul de metastazare la 30 ani: stadiul I - 2.7%, 2.7% şi 3.6%. Stadiul II - 44%, 42.9% şi 55.4%. Stadiul III - 40.6%, 26.6% şi 26.8%. Stadiul IV 7.3%, 27.9% şi 14.3%. Tratamentul preoperator atestă o diminuare istorică: 42.5%, 75% şi 50% respectiv. În 2005 având un tratament preoperator de 75% atestăm o metastazare la 3 ani de 76.8%, în 1985 respectiv 42.5% şi 61.4%. Tratamentul postoperator atestă o stagnare, rămânând axat pe chimioterapie: 1985, 2005 şi 2015 - 36.5%, 68.5%, 23.8%. Concluzii: 1. Agresivitatea tumorilor mamare rămâne o problemă crucială. 2. Atestăm o metastazare a CM haotică în primii 3 ani şi o stabilitate a progresării după 5 ani. 3. Cu fermitate putem relata că pacientele incluse în studiu ştiinţific – necesită o supraveghere la 5 ani minimum. 4.Tratamentul agresiv chimioterapic atât preoperator, posibil şi postoperator, în particular de durată, necesită a fi individualizat.

Introduction: Breast cancer (BC) is responsible for over 100,000 deaths/year in Europe and 673 deaths annually (2016) In the Republic of Moldova. Material and methods: Retrospective study, 309 patients with metastatic BC from 1985, 2005 and 2015. Results: The metastatic BC developmental course for 30 years: in 1985 and 2005 it is maintained at the age of 41-50 years, namely: 38.7% and 42.2%, versus 48.2% in 2015 aged 51-60 years. We are witnessing a slower progression of metastases to 3 years in 1985 - 61.4%, 76.8% in 2005 and 71.4% in 2015. The progression of BC returns to a more stable pace after 5 years: 11.9%, 13.6% and 12.5%. According to the stage, the metastasis process at 30 years: stage I - 2.7%, 2.7% and 3.6%. Stage II - 44%, 42.9% and 55.4%. Stage III - 40.6%, 26.6% and 26.8%. Stage IV - 7.3%, 27.9% and 14.3%. Preoperative treatment shows a historical decrease: 42.5%, 75% and 50%, respectively. In 2005, with preoperative treatment of 75%, we attest to a metastasis at 3 years of 76.8%, in 1985 respectively 42.5% and 61.4%. Postoperative treatment attests to stagnation, remains focused on chemotherapy: 1985, 2005 and 2015 - 36.5%, 68.5%, and 23.8%. Conclusions: 1. Aggressiveness of mammary tumors remains a crucial issue. 2. We are witnessing a metastasis of the chaotic CM in the first 3 years and a stability of progress after 5 years. 3. We can firmly state that patients included in the scientific study - require a minimum of 5 years of surveillance. 4. The aggressive chemotherapy treatment, both preoperatively, possibly and postoperatively, particularly in the long-term, needs to be individualized.

Cuvinte-cheie
cancer mamar, evoluţie metastatică,

breast cancer, metastatic evolution

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-165090</cfResPublId>
<cfResPublDate>2017</cfResPublDate>
<cfVol>Vol. 6</cfVol>
<cfStartPage>191</cfStartPage>
<cfISBN></cfISBN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/165090</cfURI>
<cfTitle cfLangCode='RO' cfTrans='o'>Cancerul mamar metastazant &icirc;n Republica Moldova</cfTitle>
<cfKeyw cfLangCode='RO' cfTrans='o'>cancer mamar; evoluţie metastatică; breast cancer; metastatic evolution</cfKeyw>
<cfAbstr cfLangCode='RO' cfTrans='o'><p>Introducere: Cancerul mamar (CM) este responsabil de peste 100.000 decese/an &icirc;n Europa. &Icirc;n Republica Moldova atestăm 673 decese anual (2016). Material şi metode: Studiu retrospectiv, 309 paciente cu CM metastatic din 1985, 2005 şi 2015. Rezultate: Piscul dezvoltării CM metastatic pe parcursul a 30 ani: &icirc;n 1985 şi &icirc;n 2005 se menţine la v&acirc;rsta de 41-50 ani, respectiv: 38.7% şi 42.2%, versus 48.2% &icirc;n 2015 cu v&acirc;rsta de 51-60 ani. Atestăm o progresare mai lentă a metastazelor p&acirc;nă la 3 ani &icirc;n 1985 &ndash; 61.4%, &icirc;n 2005 76.8% şi 71.4% &icirc;n 2015. Progresarea CM revine la un ritm mai stabil după 5 ani: 11.9%, 13.6% şi 12.5%. Conform stadiului, procesul de metastazare la 30 ani: stadiul I - 2.7%, 2.7% şi 3.6%. Stadiul II - 44%, 42.9% şi 55.4%. Stadiul III - 40.6%, 26.6% şi 26.8%. Stadiul IV 7.3%, 27.9% şi 14.3%. Tratamentul preoperator atestă o diminuare istorică: 42.5%, 75% şi 50% respectiv. &Icirc;n 2005 av&acirc;nd un tratament preoperator de 75% atestăm o metastazare la 3 ani de 76.8%, &icirc;n 1985 respectiv 42.5% şi 61.4%. Tratamentul postoperator atestă o stagnare, răm&acirc;n&acirc;nd axat pe chimioterapie: 1985, 2005 şi 2015 - 36.5%, 68.5%, 23.8%. Concluzii: 1. Agresivitatea tumorilor mamare răm&acirc;ne o problemă crucială. 2. Atestăm o metastazare a CM haotică &icirc;n primii 3 ani şi o stabilitate a progresării după 5 ani. 3. Cu fermitate putem relata că pacientele incluse &icirc;n studiu ştiinţific &ndash; necesită o supraveghere la 5 ani minimum. 4.Tratamentul agresiv chimioterapic at&acirc;t preoperator, posibil şi postoperator, &icirc;n particular de durată, necesită a fi individualizat.</p></cfAbstr>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>Introduction: Breast cancer (BC) is responsible for over 100,000 deaths/year in Europe and 673 deaths annually (2016) In the Republic of Moldova. Material and methods: Retrospective study, 309 patients with metastatic BC from 1985, 2005 and 2015. Results: The metastatic BC developmental course for 30 years: in 1985 and 2005 it is maintained at the age of 41-50 years, namely: 38.7% and 42.2%, versus 48.2% in 2015 aged 51-60 years. We are witnessing a slower progression of metastases to 3 years in 1985 - 61.4%, 76.8% in 2005 and 71.4% in 2015. The progression of BC returns to a more stable pace after 5 years: 11.9%, 13.6% and 12.5%. According to the stage, the metastasis process at 30 years: stage I - 2.7%, 2.7% and 3.6%. Stage II - 44%, 42.9% and 55.4%. Stage III - 40.6%, 26.6% and 26.8%. Stage IV - 7.3%, 27.9% and 14.3%. Preoperative treatment shows a historical decrease: 42.5%, 75% and 50%, respectively. In 2005, with preoperative treatment of 75%, we attest to a metastasis at 3 years of 76.8%, in 1985 respectively 42.5% and 61.4%. Postoperative treatment attests to stagnation, remains focused on chemotherapy: 1985, 2005 and 2015 - 36.5%, 68.5%, and 23.8%. Conclusions: 1. Aggressiveness of mammary tumors remains a crucial issue. 2. We are witnessing a metastasis of the chaotic CM in the first 3 years and a stability of progress after 5 years. 3. We can firmly state that patients included in the scientific study - require a minimum of 5 years of surveillance. 4. The aggressive chemotherapy treatment, both preoperatively, possibly and postoperatively, particularly in the long-term, needs to be individualized.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2017T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-11331</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11785</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-13889</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-21087</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2017T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-11331</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11331-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2017T24:00:00</cfStartDate>
<cfFamilyNames>Макидон</cfFamilyNames>
<cfFirstNames>В.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11785</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11785-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2017T24:00:00</cfStartDate>
<cfFamilyNames>Софрони</cfFamilyNames>
<cfFirstNames>Л.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-13889</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-13889-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2017T24:00:00</cfStartDate>
<cfFamilyNames>Жовмир</cfFamilyNames>
<cfFirstNames>В.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-21087</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-21087-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2017T24:00:00</cfStartDate>
<cfFamilyNames>Ткачук</cfFamilyNames>
<cfFirstNames>Д.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>